Group 1 - The core viewpoint of the article highlights the launch of Eli Lilly's Mounjaro® (tirzepatide injection multi-dose prefilled pen) on JD Health, marking it as the first and only GIP/GLP-1 receptor agonist approved for type 2 diabetes and long-term weight management [1][2] - Mounjaro® features an innovative "4-dose integration" design, allowing patients to use one fixed dose per week, thus simplifying the medication process and improving adherence [1] - The multi-dose prefilled pen can be stored at room temperature not exceeding 30°C for 30 days after the first use, enhancing convenience for patients during travel or daily use [1] Group 2 - The user experience of Mounjaro® multi-dose prefilled pen is emphasized, with simple operation steps and a fine needle that reduces pain during injection, improving patient comfort [2] - JD Health expresses excitement about collaborating with Eli Lilly to exclusively launch Mounjaro® on their platform, aiming to enhance accessibility and convenience for patients [2] - The launch of Mounjaro® is expected to benefit more patients with type 2 diabetes and obesity, promoting healthier lifestyles [2]

Core Viewpoint - Eli Lilly announced the official launch of Mounjaro® (tirzepatide injection multi-dose prefilled pen) in China, targeting adult patients with type 2 diabetes (T2DM) who have inadequate blood sugar control despite diet, exercise, and treatment with metformin and/or sulfonylureas [1] Group 1 - Mounjaro is the first and currently the only approved weekly glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist for T2DM and long-term weight management [1]